Prof. Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, MO, USA) presented the results of the DARE-19 (NCT04350593) trial [1]. DARE-19 was an international, multicentre, randomised, double-blind, placebo-controlled study of 1,250 patients who were hospitalised with COVID-19. These patients were at high risk for multiple organ failure and death. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, is known to have a protective effect in conditions such as type 2 diabetes, heart failure, and chronic kidney disease. Investigators hypothesised that this protective effect could also extend to patients with COVID-19. Patients were randomised to receive either 10 mg of dapagliflozin per day (n=625) or a placebo (n=625) for 30 days. Dual primary endpoints were prevention of organ failure –cardiac, respiratory, or kidney decompensation– or death from any cause, and recovery.
At 30 days, 86 events of organ failure or death had occurred in the placebo group (13.8%) and 70 events in the dapagliflozin group (11.2%) (HR 0.80; 95% CI 0.58–1.10; P=0.168) (see Figure). In terms of recovery, 57% of the patients in the dapagliflozin group and 57.3% of the patients in the placebo group were discharged by day 6. There were fewer adverse events in the dapagliflozin group than in the placebo group.
Figure: Primary endpoint (i.e. organ failure or death at 30 days) in the DARE-19 trial [1]

Prof. Kosiborod concluded that this evidence does not support the discontinuation of SGLT2 inhibitors in patients with COVID-19.
- Kosiborod MN. Effects of Dapagliflozin On Prevention of Major Clinical Events and Recovery in Patients with Respiratory Failure Due To COVID-19 – Main Results from the DARE-19 Randomised Trial. Abstract 406-11, ACC 2021 Scientific Session, 15–17 May.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Favourable outcomes with transcatheter atrial appendage occlusion Next Article
Nicotine by-product in urine a potential biomarker of bladder cancer recurrence »
« Favourable outcomes with transcatheter atrial appendage occlusion Next Article
Nicotine by-product in urine a potential biomarker of bladder cancer recurrence »
Table of Contents: ACC 2021
Featured articles
Electrophysiology
Favourable outcomes with transcatheter atrial appendage occlusion
Etripamil nasal spray significantly improves PSVT-related symptoms
Ablation-based rhythm control as effective as rate control in AF and HF
Finerenone reduces the risk of AF onset in patients with CKD and diabetes
Heart Failure and Cardiomyopathy
PARADISE-MI: Sacubitril/valsartan not superior to ramipril in reducing HF events
Older adults with heart failure benefit from rehabilitation programme
Quality improvement intervention fails to improve care for patients with heart failure
Sacubitril/valsartan does not reduce NT-proBNP versus valsartan alone in HFrEF
Novel use of ivabradine in reversible cardiomyopathy
Mavacamten significantly improves QoL of patients with hypertrophic cardiomyopathy
Interventional and Structural Cardiology
Men and women benefit equally from early aspirin withdrawal following PCI
Similar outcomes with fractional flow reserve and angiography-guided revascularisation
TALOS-AMI: Exploring outcomes after switching to clopidogrel versus ticagrelor at 1 month from MI
Clopidogrel monotherapy associated with better net outcomes relative to aspirin monotherapy 6-18 months after PCI
Ischaemic Heart Disease
No difference in ischaemic risk or bleeding with low vs high-dose aspirin for secondary prevention: Lessons and questions from the ADAPTABLE trial
Rivaroxaban reduces total ischaemic events after peripheral artery revascularisation
Moderate hypothermia not superior to mild hypothermia following out-of-hospital cardiac arrest
Better outcomes with invasive strategy if anatomic complete revascularisation is possible
Prevention and Health Promotion
STRENGTH trial fails to demonstrate cardioprotective effect of omega-3 fatty acids
Evinacumab lowers triglyceride levels in severe hypertriglyceridaemia
Health equity and the role of the cardiologist: 7 priorities to consider
COVID-19
Dapagliflozin fails to show a significant protective effect in COVID-19
Therapeutic anticoagulation not superior to prophylactic anticoagulation in COVID-19
Atorvastatin does not reduce mortality in COVID-19
Valvular Heart Disease
Apixaban outcomes similar to current standard of care following TAVR
Preliminary results encouraging for EVOQUE tricuspid valve replacement
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com